| Alnylam Pharmaceuticals, Inc. | $40.3b | $299.74 | +3.0% | 91.3K | |
| Ionis Pharmaceuticals, Inc. Common Stock | $12.6b | $82.34 | +4.5% | 754.5K | |
| Arrowhead Research Corporation | $11.0b | $81.69 | +1.6% | 191.6K | |
| Wave Life Sciences Ltd. Ordinary Shares | $1.3b | $5.97 | +4.9% | 282.7K | |
| CAMP4 Therapeutics Corporation Common Stock | $228.0m | $4.22 | +3.3% | 36.4K | |
| Atrium Therapeutics, Inc. Common Stock | $222.4m | $12.95 | +1.1% | 11.3K | |
| Cartesian Therapeutics, Inc. Common Stock | $221.5m | $9.44 | +4.5% | 9.4K | |
| ProQR Therapeutics N.V. Ordinary Shares | $166.5m | $1.59 | +1.0% | 502.6K | |
| Exicure, Inc. Common Stock | $20.3m | $2.67 | 0.0% | 20.6K | |
| Phio Pharmaceuticals Corp. Common Stock | $12.9m | $0.99 | 0.0% | 20.7K |